Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 2CNS 1

Conditions

Obesity 2Weight Loss 1Sexual Infantilism 1Polycystic Ovary Syndrome 1

Interventions

naloxegol 5Metformin 4alvimopan 3Radiotherapy 3tegaserod 2Testosterone Propionate 2Surveys and Questionnaires 2Standard of Care 2Liraglutide 2Glutamine 2Fibroblast Growth Factor 7 2Exenatide 2Early Intervention, Educational 2semaglutide 1prucalopride 1oxycodone-acetaminophen 1oxycodone naloxone combination 1lime 1dapagliflozin 1cyclohexaneacetic acid 1bicalutamide 1acetaminophen, hydrocodone drug combination 1Testosterone 1Taxes 1Tamoxifen 1Tadalafil 1Sugars 1Sugammadex 1Sucralfate 1Sodium-Glucose Transporter 2 Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Exenatide × Other × Clear all
NCT02664441 2022-05-05

ECHO

Seattle Children's Hospital

Phase 3 Completed
42 enrolled 26 charts
Other

Obesity, Weight Loss, Sexual Infantilism

NCT02635386 2021-01-29

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Woman's

Phase 3 Completed
119 enrolled 34 charts
Other

Obesity, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡